Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Danusertib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA known ✓ | O14965 | 18/20 | 1.00 |
| ▸ | AURKB known ✓ | Q96GD4 | 8/20 | 1.00 |
| ▸ | AURKC known ✓ | Q9UQB9 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 4/20 | 1.00 |
| ▸ | CDK2 | P24941 | 4/20 | 1.00 |
| ▸ | NTRK1 | P04629 | 3/20 | 1.00 |
| ▸ | RET | P07949 | 3/20 | 1.00 |
| ▸ | FGFR1 | P11362 | 3/20 | 1.00 |
| ▸ | LIMK1 | P53667 | 3/20 | 1.00 |
| ▸ | BCR | P11274 | 3/20 | 1.00 |
| ▸ | FLT3 | P36888 | 3/20 | 1.00 |
| ▸ | PLK4 | O00444 | 2/20 | 1.00 |
| ▸ | JAK2 | O60674 | 2/20 | 1.00 |
| ▸ | MAP4K4 | O95819 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | FES | P07332 | 2/20 | 1.00 |
| ▸ | LYN | P07948 | 2/20 | 1.00 |
| ▸ | SRC | P12931 | 2/20 | 1.00 |
| ▸ | PHKG2 | P15735 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Danusertib SCHEMBL2685432 | 1.00 | AURKA (1.00) | AURKAAURKBABL1CDK2NTRK1 | |
| Danusertib SCHEMBL29453494 | 0.99 | AURKA (0.98) | AURKAAURKBABL1CDK2NTRK1 | |
| SCHEMBL1377925 | 0.92 | AURKA (0.86) | AURKAAURKBABL1CDK2NTRK1 | |
| SCHEMBL26184014 | 0.92 | AURKA (0.86) | AURKAAURKBABL1CDK2NTRK1 | |
| SCHEMBL9998664 | 0.92 | AURKA (0.86) | AURKAAURKBABL1CDK2NTRK1 | |
| SCHEMBL25277403 | 0.92 | AURKA (0.86) | AURKAAURKBABL1CDK2NTRK1 | |
| SCHEMBL1377947 | 0.92 | AURKA (0.85) | AURKAAURKBABL1CDK2NTRK1 | |
| SCHEMBL3486691 | 0.92 | AURKA (0.85) | AURKAAURKBABL1CDK2NTRK1 | |
| SCHEMBL3486749 | 0.92 | AURKA (0.85) | AURKAAURKBABL1CDK2NTRK1 | |
| SCHEMBL2922037 | 0.92 | AURKA (0.85) | AURKAAURKBABL1CDK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2133 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122057044-A | Nanometer liposome delivery system for targeting PLK1/Aurora kinase and application thereof in oral squamous cell carcinoma treatment | 徐州医科大学 | 2026-05-19 | — | — | CN | claimed |
| EP-4729519-A1 | CRYSTAL FORM OF ENPP1 INHIBITOR | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-04-22 | — | — | EP | claimed |
| US-12577255-B2 | MDM2-based modulators of proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2026-03-17 | — | — | US | claimed |
| EP-4048260-B1 | COMBINATION OF SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR USE IN TREATING A HEMATOLOGICAL MALIGNANCY | CELGENE CORP (US) | 2026-03-11 | — | — | EP | claimed |
| EP-4704832-A2 | BIFUNCTIONAL SMALL MOLECULES TO TARGET THE SELECTIVE DEGRADATION OF CIRCULATING PROTEINS | Biohaven Therapeutics Ltd. (VG) | 2026-03-11 | — | — | EP | claimed |
| WO-2026043541-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TUFTS MEDICAL CENTER, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| US-20260022117-A1 | COMPOUNDS AND METHODS FOR THE ENHANCED DEGRADATION OF TARGETED PROTEINS | ARVINAS OPERATIONS INC (US) | 2026-01-22 | — | — | US | claimed |
| EP-4667458-A1 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF CANCER, COMPRISING SOS1 INHIBITOR AND ANTICANCER DRUG | Kanaph Therapeutics Inc. (KR) | 2025-12-24 | — | — | EP | claimed |
| US-12485178-B2 | Bifunctional small molecules to target the selective degradation of circulating proteins | YALE UNIVERSITY (US) | 2025-12-02 | — | — | US | claimed |
| US-20250352551-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS AND SECOND ACTIVE AGENTS FOR COMBINED USE | CELGENE CORPORATION | 2025-11-20 | — | — | US | claimed |
| EP-2788504-B1 | METHOD OF DETERMINATION OF CANCER CELL DRUG SENSITIVITY TOWARDS AURORA KINASE INHIBITORS | PALACKY UNIVERSITY OLOMOUC (CZ) | 2016-08-17 | — | — | EP | claimed |
| US-20140336073-A1 | METHOD OF DETERMINATION OF CANCER CELL DRUG SENSITIVITY TOWARDS AURORA KINASE INHIBITORS | PALACKY UNIVERSITY, OLOMOUC (CZ) | 2014-11-13 | — | — | US | claimed |
| EP-2602330-A1 | Method of determination of cancer cell drug sensitivity towards Aurora kinase inhibitors and overcoming their resistance | Palacky University, Olomouc (CZ) | 2013-06-12 | — | — | EP | claimed |
| US-8084455-B2 | Use of a kinase inhibitor for the treatment of particular resistant tumors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-12-27 | — | — | US | claimed |
| EP-1644376-B1 | PYRROLO 3,4-c PYRAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES SRL (IT) | 2010-09-08 | — | — | EP | claimed |
| US-20100035876-A1 | Use of a Kinase Inhibitor for the Treatment of Particular Resistant Tumors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2010-02-11 | — | — | US | claimed |
| EP-2004180-A2 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | Nerviano Medical Sciences S.r.l. (IT) | 2008-12-24 | — | — | EP | claimed |
| WO-2007113212-A2 | USE OF A KINASE INHIBITOR FOR THE TREATMENT OF PARTICULAR RESISTANT TUMORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2007-10-11 | — | — | WO | claimed |
| US-7141568-B2 | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2006-11-28 | — | — | US | claimed |
| US-20050032839-A1 | Pyrrolo[3,4-c]pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PHARMACIA ITALIA S.P.A. (IT) | 2005-02-10 | — | — | US | claimed |